Medivir (Q3 Review): New Phase II Study - Redeye

Redeye comments on Medivir’s Q2 report. A rights issue of cSEK150m was announced, which will fund a new investigator-sponsored trial, smaller than previously but with a control arm. Remetinostat was outlicensed to Biossil for up to USD60m in milestones, a limited deal. We update our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1136671/medivir-q3-review-new-phase-ii-study?utm_source=finwire&utm_medium=RSS